Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries

References

• GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi:10.1016/S0140-6736(17)32152-9
   PubMed Web of Science ®Google Scholar
• Seiglie JA, Marcus M-E, Ebert C, et al. Diabetes prevalence and its relationship with education, wealth, and BMI in 29 low- and middle-income countries. Diabetes Care. 2020;43:767–775. doi:10.2337/dc19-1782
   PubMed Web of Science ®Google Scholar
• Mechanick JI. Adiposity-based chronic disease—obesity re-worked. US Endocrinol. 2016;12:102. doi:10.17925/USE.2016.12.02.102
   Google Scholar
• Reinehr T. Lifestyle intervention in childhood obesity: changes and challenges. Nat Rev Endocrinol. 2013;9:607–614. doi:10.1038/nrendo.2013.149
   Web of Science ®Google Scholar
• Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT. Dysglycemia-based chronic disease: an American Association of Clinical Endocrinologists position statement. Endocr Pract. 2018;24:995–1011. doi:10.4158/PS-2018-0139
   PubMed Web of Science ®Google Scholar
• Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps. J Am Coll Cardiol. 2020;75:539–555. doi:10.1016/j.jacc.2019.11.046
   Web of Science ®Google Scholar
• Kalra S, Unnikrishnan AG, Baruah MP, Sahay R, Bantwal G. Metabolic and energy imbalance in dysglycemia-based chronic disease. Diabetes Metab Syndr Obes. 2021;14:165–184. doi:10.2147/DMSO.S286888
   Web of Science ®Google Scholar
• Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents. Endocr Rev. 2019;40:1447–1467. doi:10.1210/er.2018-00141
   PubMed Web of Science ®Google Scholar
• Gobardhan SN, Dimitriu-Leen AC, van Rosendael AR, et al. Prevalence by computed tomographic angiography of coronary plaques in South Asian and white patients with type 2 diabetes mellitus at low and high risk using four cardiovascular risk scores (UKPDS, FRS, ASCVD, and JBS3). Am J Cardiol. 2017;119:705–711. doi:10.1016/j.amjcard.2016.11.029
   Web of Science ®Google Scholar
• Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005;115:1699–1702. doi:10.1172/JCI25758
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Sparks LM. Metabolic flexibility in health and disease. Cell Metab. 2017;25:1027–1036. doi:10.1016/j.cmet.2017.04.015
   PubMed Web of Science ®Google Scholar
• Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab. 2008;295:E1009–E1017. doi:10.1152/ajpendo.90558.2008
   PubMed Web of Science ®Google Scholar
• Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23:804–814. doi:10.1038/nm.4350
   PubMed Web of Science ®Google Scholar
• Muoio DM. Metabolic inflexibility: when mitochondrial indecision leads to metabolic gridlock. Cell. 2014;159:1253–1262. doi:10.1016/j.cell.2014.11.034
   PubMed Web of Science ®Google Scholar
• Wilcox G. Insulin and insulin resistance. Clin Biochem Rev. 2005;26:19–39.
   PubMedGoogle Scholar
• Gonzalez-Zacarias AA, Mavarez-Martinez A, Arias-Morales CE, Stoicea N, Rogers B. Impact of demographic, socioeconomic, and psychological factors on glycemic self-management in adults with type 2 diabetes mellitus. Front Public Health. 2016;4. doi:10.3389/fpubh.2016.00195
   Web of Science ®Google Scholar
• Popkin BM, Reardon T. Obesity and the food system transformation in Latin America. Obes Rev. 2018;19:1028–1064. doi:10.1111/obr.12694
   PubMed Web of Science ®Google Scholar
• Unger JB, Reynolds K, Shakib S, et al. Acculturation, physical activity, and fast-food consumption among Asian-American and Hispanic adolescents. J Community Health. 2004;29:467–481. doi:10.1007/s10900-004-3395-3
   PubMed Web of Science ®Google Scholar
• Fall CH. Non-industrialised countries and affluence. Br Med Bull. 2001;60:33–50. doi:10.1093/bmb/60.1.33
   PubMed Web of Science ®Google Scholar
• Iwelunmor J, Blackstone S, Veira D, et al. Toward the sustainability of health interventions implemented in sub-Saharan Africa: a systematic review and conceptual framework. Implement Sci. 2016;11(43):1–27.
   Google Scholar
• Łuczyński W, Głowińska-Olszewska B, Bossowski A. Empowerment in the treatment of diabetes and obesity. J Diabetes Res. 2016;2016:e5671492. doi:10.1155/2016/5671492
   Web of Science ®Google Scholar
• Lopez Stewart G, Tambascia M, Rosas Guzmán J, et al. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007;22:12–20. doi:10.1590/S1020-49892007000600002
   PubMed Web of Science ®Google Scholar
• Anjana RM, Deepa M, Subashini R, et al. Temporal changes in diabetes prevalence and achievement of care goals in urban South Asia from 2010 to 2016 – the center for cardio-metabolic risk reduction in South Asia Study. Diabetic Med. 2021;38(e14424). doi:10.1111/dme.14424
   Web of Science ®Google Scholar
• Ali MK, Singh K, Kondal D, et al. Effectiveness of a multicomponent quality improvement strategy to improve achievement of diabetes care goals. Ann Intern Med. 2016;165:399–408. doi:10.7326/M15-2807
   Web of Science ®Google Scholar
• Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359:1618–1620. doi:10.1056/NEJMe0807625
   PubMed Web of Science ®Google Scholar
• Pedersen O, Gaede P. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study. Metabolism. 2003;52:19–23. doi:10.1016/S0026-0495(03)00213-0
   PubMed Web of Science ®Google Scholar
• Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–964. doi:10.1016/S2213-8587(17)30327-3
   PubMed Web of Science ®Google Scholar
• Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dyslipidemia. Diabetes Ther. 2016;7:203–219. doi:10.1007/s13300-016-0167-x
   PubMed Web of Science ®Google Scholar
• Non-HDL cholesterol and atherosclerotic cardiovascular disease. Available from: https://www.japi.org/x264d464/non-hdl-cholesterol-and-atherosclerotic-cardiovascular-disease. Accessed January 20, 2022.
   Google Scholar
• Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–1309. doi:10.1001/jama.2012.366
   PubMed Web of Science ®Google Scholar
• Iyengar SS, Puri R, Narasingan SN. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1. J Assoc Physicians India. 2016;64:7–52.
   Google Scholar
• Reiner Z, Catapano AL, De Backer G; Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818. doi:10.1093/eurheartj/ehr158
   PubMed Web of Science ®Google Scholar
• Anjana RM, Baskar V, Nair ATN, et al. Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Res Care. 2020;8(e001506). doi:10.1136/bmjdrc-2020-001506
   Web of Science ®Google Scholar
• Zou X, Zhou X, Zhu Z, Ji L. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol. 2019;7:9–11. doi:10.1016/S2213-8587(18)30316-4
   Web of Science ®Google Scholar
• Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5:585–596. doi:10.1016/S2213-8587(17)30174-2
   PubMed Web of Science ®Google Scholar
• Pati MK, Swaroop N, Kar A, et al. A narrative review of gaps in the provision of integrated care for noncommunicable diseases in India. Public Health Rev. 2020;8:41.
   Google Scholar
• Patel SA, Sharma H, Mohan S, et al. The Integrated Tracking, Referral, and Electronic Decision Support, and Care Coordination (I-TREC) program: scalable strategies for the management of hypertension and diabetes within the government healthcare system of India. BMC Health Serv Res. 2020;20:1022. doi:10.1186/s12913-020-05851-w
   Web of Science ®Google Scholar
• Gupta M, Brister S, Verma S. Is South Asian ethnicity an independent cardiovascular risk factor? Can J Cardiol. 2006;22:193–197. doi:10.1016/S0828-282X(06)70895-9
   PubMed Web of Science ®Google Scholar
• Kasliwal RR, Mahansaria K, Bansal M. Cardiovascular risk algorithms and their applicability to Indians; 2010.
   Google Scholar
• Findlay SG, Kasliwal RR, Bansal M, Tarique A, Zaman A. A comparison of cardiovascular risk scores in native and migrant South Asian populations. SSM Popul Health. 2020;11:100594.
   Web of Science ®Google Scholar
• Bansal M, Kasliwal RR, Trehan N. Relationship between different cardiovascular risk scores and measures of subclinical atherosclerosis in an Indian population. Indian Heart J. 2015;67:332–340. doi:10.1016/j.ihj.2015.04.017
   PubMedGoogle Scholar
• Lloyd-Jones Donald M, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–798. doi:10.1161/CIRCULATIONAHA.105.548206
   Web of Science ®Google Scholar
• Daviglus ML. Cardiovascular risk profile earlier in life and medicare costs in the last year of life. Arch Intern Med. 2005;165(1028):1028. doi:10.1001/archinte.165.9.1028
   Google Scholar
• Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1. Circ Res. 2017;121:677–694. doi:10.1161/CIRCRESAHA.117.308903
   PubMed Web of Science ®Google Scholar
• Suzanne O. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;41:1006–1009. doi:10.1161/01.HYP.0000070905.09395.F6
   Web of Science ®Google Scholar
• Karachaliou F, Simatos G, Simatou A. The challenges in the development of diabetes prevention and care models in low-income settings. Front Endocrinol. 2020;11. doi:10.3389/fendo.2020.00518
   Web of Science ®Google Scholar
• Rushforth B, McCrorie C, Glidewell L, Midgley E, Foy R. Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review. Br J Gen Pract. 2016;66:e114–e127. doi:10.3399/bjgp16X683509
   PubMed Web of Science ®Google Scholar
• Asif M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J Educ Health Promot. 2014;3. doi:10.4103/2277-9531.127541
   Google Scholar
• Liu K, Daviglus ML, Loria CM, et al. Healthy lifestyle through young adulthood and presence of low cardiovascular disease risk profile in middle age: the coronary artery risk development in (Young) Adults (CARDIA) Study. Circulation. 2012;125:996–1004. doi:10.1161/CIRCULATIONAHA.111.060681
   PubMed Web of Science ®Google Scholar
• Uusitupa M. Good news from the Da Qing Diabetes Prevention Outcome Study—healthy lifestyles result in long-term cardiovascular benefits. Ann Transl Med. 2019;7:S368–S368. doi:10.21037/atm.2019.08.123
   Web of Science ®Google Scholar
• Thankappan KR, Sathish T, Tapp RJ, et al. A peer-support lifestyle intervention for preventing type 2 diabetes in India: a cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. PLoS Med. 2018;15:e1002575. doi:10.1371/journal.pmed.1002575
   PubMed Web of Science ®Google Scholar
• Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:914–926. doi:10.1016/j.jacc.2018.02.085
   PubMed Web of Science ®Google Scholar
• Misra A, Sharma R, Gulati S, et al. Consensus dietary guidelines for healthy living and prevention of obesity, the metabolic syndrome, diabetes, and related disorders in Asian Indians. Diabetes Technol Ther. 2011;13:683–694. doi:10.1089/dia.2010.0198
   PubMed Web of Science ®Google Scholar
• Mattei J, Malik V, Wedick NM, et al. A symposium and workshop report from the global nutrition and epidemiologic transition initiative: nutrition transition and the global burden of type 2 diabetes. Br J Nutr. 2012;108:1325–1335. doi:10.1017/S0007114512003200
   PubMed Web of Science ®Google Scholar
• World Health Organization & Commission on Ending Childhood Obesity. Report of the commission on ending childhood obesity; 2016.
   Google Scholar
• Weber MB, Ranjani H, Staimez LR, et al. The stepwise approach to diabetes prevention: results from the D-CLIP Randomized Controlled Trial. Diabetes Care. 2016;39:1760–1767. doi:10.2337/dc16-1241
   Web of Science ®Google Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–S73. doi:10.1161/01.cir.0000437741.48606.98
   PubMed Web of Science ®Google Scholar
• World Health Organization. More active people for a healthier world: global action plan on physical activity 2018–2030; 2018.
   Google Scholar
• Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension: JACC health promotion series. J Am Coll Cardiol. 2018;72:1278–1293. doi:10.1016/j.jacc.2018.07.008
   Web of Science ®Google Scholar
• Correia JC, Lachat S, Lagger G, et al. Interventions targeting hypertension and diabetes mellitus at community and primary healthcare level in low- and middle-income countries: a scoping review. BMC Public Health. 2019;19(1542). doi:10.1186/s12889-019-7842-6
   Web of Science ®Google Scholar
• Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82:222S–225S. doi:10.1093/ajcn/82.1.222S
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378:156–167. doi:10.1016/S0140-6736(11)60698-3
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486
   PubMed Web of Science ®Google Scholar
• Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18(Suppl 2):S10–15. doi:10.1002/dmrr.249
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2784–2791. doi:10.1210/jcem.87.6.8567
   PubMed Web of Science ®Google Scholar
• Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295:14379–14390. doi:10.1074/jbc.REV120.008387
   PubMed Web of Science ®Google Scholar
• Solis-Herrera C, Daniele G, Alatrach M, et al. Increase in endogenous glucose production with SGLT2 inhibition is unchanged by renal denervation and correlates strongly with the increase in urinary glucose excretion. Diabetes Care. 2020;43:1065–1069. doi:10.2337/dc19-2177
   Web of Science ®Google Scholar
• Husain M, Bain SC, Holst AG, et al. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol. 2020;19(156). doi:10.1186/s12933-020-01106-4
   Web of Science ®Google Scholar
• Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Ther. 2019;10:1733–1752. doi:10.1007/s13300-019-00680-5
   PubMed Web of Science ®Google Scholar
• Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143–156. doi:10.1038/nrendo.2013.256
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174. doi:10.1172/JCI13505
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci. 2020;5:632–644. doi:10.1016/j.jacbts.2020.02.004
   PubMedGoogle Scholar
• Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40(S28–S34):S28–S34. doi:10.1016/S1262-3636(14)72693-X
   Web of Science ®Google Scholar
• Costello RA, Nicolas S, Shivkumar A. Sulfonylureas. In: StatPearls. StatPearls Publishing; 2021.
   Google Scholar
• Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19(151). doi:10.1007/s11892-019-1270-y
   Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16:642–653. doi:10.1038/s41574-020-0399-8
   PubMed Web of Science ®Google Scholar
• Tran KL, Park YI, Pandya S, et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10:178–188.
   PubMed Web of Science ®Google Scholar
• Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30:202–210. doi:10.2337/ds16-0026
   PubMedGoogle Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28:154–163. doi:10.2337/diacare.28.1.154
   PubMed Web of Science ®Google Scholar